Article

Preservative system in recalled drops unique from company's other lines

The preservative system used to manufacture Systane Free Liquid Gel lubricating eye drops (Alcon Laboratories) is distinctly different from that of the company's other products, including travoprost ophthalmic solution 0.004% (Travatan), according to the company.

The preservative system used to manufacture Systane Free Liquid Gel lubricating eye drops (Alcon Laboratories) is distinctly different from that of the company's other products, including travoprost ophthalmic solution 0.004% (Travatan), according to the company.

Alcon is emphasizing the differences in the products' preservative systems to shore up support for its products after it discovered that a faulty preservative in its Systane Free Liquid Gel allowed mold to grow.

The company pulled the product from store shelves Dec. 15 and initiated a voluntary recall with no plans to return it to the market.

The company said its travoprost ophthalmic solution 0.004% for reducing IOP in patients with open-angle glaucoma, however, uses a novel ionic-buffered preservative system called sofZia, which is an extension of its borate/polyol preservative systems. Nitrogen is an essential nutrient for the growth of microbial contaminants.

"Travatan Z solution does not contain any nitrogen source, such as AMP, which is present in Systane Free Liquid Gel," the letter stated.

"Alcon has demonstrated that the sofZia preservative system is robust and withstands multiple challenges of high levels of ocular pathogens, such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus niger," the letter stated. "In addition, other in-use testing with high-level challenges of Fusarium solani, Ralstonia pickettii, Staphylococcus epidermidis, Streptococcus pneumoniae, and Haemophilus influenzae demonstrated that Travatan Z solution is effectively preserved."

The letter was signed by Michael V.W. Bergamini, PhD, vice president, glaucoma development, and Barry A. Schlech, PhD, vice president, pharmaceutical microbiology, both of Alcon Research Ltd.

Meanwhile, the original formulation of Systane uses the Polyquad preservative system, which has been used safely for more than 20 years to prevent contamination of eye-care products, the company said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.